Parties to Discuss Growing Case List, Attorney Appointments this Week at Lipitor Lawsuit Status Conference

Published on March 25, 2014 by Sandy Liebhard

Text-Size:A A A+


A federal Lipitor lawsuit litigation created last month in South Carolina federal court is gearing up for its first status conference on Thursday, where parties will discuss matters related to the cholesterol-lowering statin.

According to court documents, the March 27th meeting will be the first to take place since the proceeding’s recent creation in the U.S. District Court, District of South Carolina. When cases were originally transferred there on February 18th, just 56 Lipitor diabetes lawsuits had been filed by women who claim that Pfizer failed to adequately patients and their doctors about risks associated with its product.

A Case List updated March 13th by the U.S. Judicial Panel on Multidistrict Litigation (JPML) shows 270 Lipitor lawsuits now filed in South Carolina, which may serve as an indicator of its future progress.

Among the items listed on the meeting’s agenda, a recent Case Management Order indicates that a possible liaison counsel and the creation of various committees to serve in the litigation will be among the matters scheduled for discussion.

New Study May Affect Lipitor Diabetes Litigation

As this litigation continues to grow, the findings of a new study published in the European Journal of Preventive Cardiology may ignite more Lipitor case filings, and affect those currently pending in South Carolina federal court. The research, which was released in March 2014, looked at data from 14 studies—and 46,000 patients who took either a statin or placebo—and found that 1 in 5 diabetes cases could stem from a cholesterol-lowering drug like Lipitor. Some 3% of statin users were later diagnosed with Type 2 diabetes, the research found, compared to 2.4% of those taking a placebo.

Two years ago, another study involving Lipitor was published in JAMA: Internal Medicine, and found that post-menopausal women may be at an increased risk for developing the disease. After being published in January 2012, the U.S. Food and Drug Administration (FDA) mandated the following month that all statin manufacturers adjust the labeling on their products to include the risk for diabetes.

The British Medical Journal reported in May 2013 that users of Lipitor may be 22 percent more likely to develop the disease.

File a Lipitor Lawsuit

Contact our Firm to learn more about the growing Lipitor lawsuit litigation, and find out whether you can pursue a claim against Pfizer. Call us now at .